High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia-Reference-Cited by-同舟云学术

High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia

Published:2021-05 Issue:5 Volume:14 Page:101048
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Wander Priscilla,Arentsen-Peters Susan T.C.J.M.^ORCID,Pinhanҫos Sandra S.^ORCID,Koopmans Bianca,Dolman M.Emmy M.,Ariese Rijndert^ORCID,Bos Frank L.^ORCID,Castro Patricia Garrido,Jones Luke^ORCID,Schneider Pauline,Navarro Miriam Guillen,Molenaar Jan J.,Rios Anne C.,Zwaan C. Michel,Stam Ronald W.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate;Abrahamsson;J. Clin. Oncol.,2011

2. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses;Creutzig;Br. J. Haematol.,2010

3. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial;Gibson;Br. J. Haematol.,2011

4. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial;Rubnitz;Lancet Oncol.,2010

5. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese childhood AML cooperative study group;Tsukimoto;J. Clin. Oncol.,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing antiparasitic drugs for the treatment of other diseases;Advances in Antiparasitic Therapies and Drug Delivery;2024

2. Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma;2023-11-04

3. Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug;Biomedicines;2022-12-14

4. Clinical profile in KMT2A-SEPT6-positive acute myeloid leukemia: Does it often co-occur with NRAS mutations?;Frontiers in Medicine;2022-09-21

5. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia;Leukemia;2022-03-30